EGFR and non-small cell lung carcinoma: Real-world evidence shows that the survival outcomes of patients with advanced NSCLC with common EGFR mutations [10], uncommon EGFR mutations [12, 14, 15], or poor PS [16, 17] were better with afatinib than with gefitinib or erlotinib.